01Source
Which adipose source?
Donor area, harvest method and lipoaspirate handling influence quantity and composition.
Stromal Vascular Fraction · Istanbul
Stromal Vascular Fraction · Istanbul
Stromal Vascular Fraction (SVF)
SVF is derived from the patient's adipose tissue and may contain stromal, endothelial, perivascular, immune and blood-cell populations with variable matrix. The complete mechanical or enzymatic route determines which final product exists.
SVF is not a pure stem-cell population. Cell count, viability, characterisation, sterility, residual processing material, intended function and local regulatory status must be considered for the specific product.
Quick Orientation
Four product-identity questions
The initials SVF do not define a comparable final preparation.
Source tissue, processing route, product characterisation, intended function and jurisdiction all influence medical and regulatory assessment.
02Process
Which processing route?
Mechanical fragmentation and enzymatic dissociation do not produce the same material.
03Quality
Which release data?
Cell count, viability, profile, matrix, sterility and residues are stated only when measured.
04Use
Which purpose and location?
Hair target, delivery route and treatment jurisdiction shape evidence and regulatory review.
What SVF Means
Heterogeneous fraction · multiple cell types
SVF is a mixed adipose-tissue fraction, not one cell population.
After mature fat cells are removed or disrupted, uncultured material may include endothelial, perivascular, stromal, immune and blood-cell populations. Proportions vary with patient and process.
What may be characterised
- Describe a fresh patient-specific tissue or cell fraction
- Report measured cell count, viability and appropriate phenotype where available
- Link one identified product to one defined scalp purpose
- Maintain process, sterility, traceability and follow-up records
What cannot be assumed
- Be called a pure or dosed stem-cell treatment without valid analysis
- Be equated with nanofat, microfat or culture-expanded cells
- Transfer evidence between different preparations or clinical targets
- Bypass quality or regulatory requirements because it is autologous
Scientific nomenclature helps describe the material, but it does not replace product- and purpose-specific regulatory assessment where treatment would occur.
Medical and Regulatory Suitability
Indication · harvest · product · jurisdiction
Five checks come before adipose-tissue collection or SVF use.
Personal examination, a defined donor procedure, product-release information and the current local framework must align before any plan is considered.
- 01
Define the clinical indication
The hair diagnosis is compared with established treatment, observation and no procedure.
- 02
Review procedural health
Medicines, bleeding, infection, anaesthetic, tumour history and wound healing are considered.
- 03
Examine the donor area
Adipose distribution, skin, scars, previous liposuction and a defensible harvest volume are assessed.
- 04
Identify the final product
Tissue or cellular SVF, processing, release data, amount, target layer and traceability are specified.
- 05
Check status and endpoint
Jurisdiction, classification, permissions, baseline, review time and stopping rule are considered.
Harvest, Processing and Release
Lipoaspirate · isolation · identified product
Traceability must run from donor tissue to the intended target.
A device name does not establish SVF quality. Environment, timing, material contact, isolation, washing, testing and delivery belong to one chain.
01Harvest
Collect lipoaspirate safely
Donor area, anaesthetic, cannula, pressure and collected amount are documented for the individual.
- Maintain sterile identification
- Monitor bleeding and fluid balance
- Plan donor-site aftercare
02Isolation
Name mechanical or enzymatic steps
Tissue fragmentation and enzyme-released cellular suspension require separate process records.
- Document every processing stage
- Record washing, filtration and centrifugation
- State matrix retention and residues
03Release
Verify before any delivery
Only an identified preparation is considered for the planned target under a separate consent decision.
- Use measured quality data
- Record amount and delivery layer
- Preserve patient-product traceability
With enzymatic processing, enzyme type, exposure, neutralisation or washing and residual-material control form part of product release.
Evidence and Limits
Different products · small cohorts
A favourable signal applies only to a comparable SVF product and hair endpoint.
Early studies in non-scarring hair loss use different isolation methods, adjuncts and measurement techniques. They do not establish one routine SVF protocol.
Hair data remain limited
Published cohorts and small trials do not provide robust, product-independent conclusions.
Processing changes identity
Mechanical tissue SVF and enzymatically released cellular SVF cannot share evidence automatically.
Other tissues are not scalp evidence
Skin, scar and wound studies use different products, anatomy and endpoints.
Safety knowledge is incomplete
Harvest-related events and rare product or delivery complications need longer, systematic follow-up.
Standardised product data, independent controlled comparisons and long-term surveillance remain limited; a stem-cell or hair-restoration promise is not supported.
Individual SVF Decision Plan
No cell package · no automatic series
Product release and regulatory review come before a clinical plan.
An invasive tissue pathway is considered only when the indication, product, quality information, alternatives and follow-up are clear before harvest.
Secure the baseline
Record diagnosis, scalp target, donor area, established options and personal risk factors.
Justify the product route
Explain mechanical or enzymatic processing, quality data, status, amount and target layer.
Limit the first decision
There is no automatic course of sessions; harvest and delivery need a narrow clinical purpose.
Reassess the balance
Donor healing, objective findings, burden and alternatives determine whether the pathway ends.
Healing and Follow-Up
Donor area · target tissue · hair endpoint
Early wound response is not evidence of a cellular effect.
Harvest and scalp areas are reviewed on separate timelines. Hair findings are assessed only after acute procedure-related changes settle.
- 01Early
First days
Pain, swelling, bruising, small wounds and tenderness may affect donor and target areas.
- 02Safety
Following weeks
Wound healing, infection, fluid collection, contour, nodules and persistent inflammation are assessed.
- 03Endpoint
Following months
The selected hair endpoint is repeated with the same method and without early swelling effects.
- 04Decision
Longer-term review
Findings, adverse effects, donor burden and established alternatives are reconsidered.
Risks and Alternatives
Autologous does not mean pure or risk-free
SVF combines harvest, processing and delivery risks.
Patient-derived tissue does not prevent contamination, product misidentification, unexpected inflammation, local complications or lack of benefit.
01Donor
Adipose harvest
Pain, bruising, bleeding, infection, fluid collection, scar, altered sensation or contour change may occur.
02Process
Product and target
Contamination, residues, cell damage, inflammation, infection, nodules or tissue injury are possible.
03Decision
Delivery and alternatives
Incorrect placement can cause serious harm; established treatment, observation or no procedure may be safer.
04Decision
Withhold or stop
Treatment is withheld or stopped when the indication, consent, safety controls or follow-up cannot support a proportionate plan.
Unexpected or worsening symptoms at the donor or target site need prompt in-person assessment and product-specific documentation.
Istanbul and Follow-Up
Travel around harvest and product review
An SVF decision requires more than a treatment appointment.
Travel, examination, possible harvest, product release, early review and later follow-up must form one medically coherent pathway.
01Before travel
Organise clinical records
Current diagnoses, medicines, previous procedures and relevant pathology frame the personal review.
02Bağdat Caddesi
Assess indication and donor
Product route, quality data, regulatory setting, established options and travel burden are considered.
03Procedure
Keep the procedure conditional
Only after full suitability would harvest, processing, release and any delivery be considered.
04After return
Plan return care
Donor care, warning signs, local assessment access, records and review timing are agreed.
The Doctor Aslan Approach
Product clarity before cell language
Source, processing, characterisation, purpose and status matter more than the initials SVF.
A responsible assessment may end without tissue collection. A plan requires an identified product, a defensible clinical purpose and an appropriate current framework.
Diagnosis before harvest
The hair indication is examined and compared with less invasive and established pathways.
Keep processing visible
Donor, mechanical or enzymatic route, release data, amount, layer and traceability remain explicit.
Limit cell terminology
Heterogeneous SVF is not presented as a pure cell population or a defined stem-cell dose.
Bind evidence to product
Clinical interpretation remains tied to the actual preparation, jurisdiction and endpoint.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about stromal vascular fraction; no personal diagnosis or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is Stromal Vascular Fraction (SVF)?+
Stromal Vascular Fraction (SVF) is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for Stromal Vascular Fraction (SVF)?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Define the product · check the framework